Seres therapeutics' investigational ser-109 ecospor iv study data published in jama network open

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced the publication of data from its phase 3 ecospor iv trial (clinicaltrials.gov identifier: nct03183128) in jama network open that reinforce previously published results from the phase 3 ecospor iii study on the investigational microbiome therapeutic ser-109 for the prevention of recurrent c. difficile infection (rcdi). with nearly 156,000 cases in the u.s.
MCRB Ratings Summary
MCRB Quant Ranking